SEATTLE–(BUSINESS WIRE)–Empower Clinics, Empower Clinics Inc. (CSE: EPW; FRA: 8EC), a leading owner and operator of medical cannabis and wellness clinics in the US, today provided a corporate update on operations and strategic initiatives.
“Chicago’s opening marked the beginning of our national clinic expansion strategy via a combination of organic growth and accretive acquisitions”
As of August 31, the company has more than 25,000 patients under care with medical cannabis treatments in Oregon and Washington. The patient base in Oregon represents approximately one-third of the state’s total medical card issuance. In addition, the company has an historical patient database of more than 120,000 in the two states.
On September 12, Empower announced the opening of its flagship Chicago clinic. In Illinois, the company seeks to expand its operations and achieve a leadership position as it executes on parallel national clinic and product strategies. There is currently an opioid epidemic in the United States and the company’s announced Chicago facility closely followed the endorsement by Illinois Governor Bruce Rauner of medical cannabis as a frontline treatment and alternative for patients with a new statewide measure he signed into law on Aug 28.
Chicago’s opening marked the beginning of our national clinic expansion strategy via a combination of organic growth and accretive acquisitions,” said Craig Snyder, Empower CEO. “As we build upon our clinic expansion strategy we will concurrently execute on our product strategy, leveraging our extensive medical patient base. We look forward to updating the market in due course on our medically focused THC and CBD branded products, Sollievo, through licensing and distribution agreements.
Empower’s CBD Sollievo products, soon to launch nationally, specifically target the most common qualifying medical conditions, involving pain, sleep, stress, and digestion. Empower’s CBD products are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.
Medical cannabis is becoming a mainstream treatment in the United States with government approval in 30 states and the District of Columbia currently, and the ability to legally distribute certain CBD products nationally. Empower intends to have a leadership role, as well as be at the forefront in the fight against opioid addiction, through the establishment of its national clinic chain and specialization in education and technology related to medical cannabis.
Snyder continued: “We have a very strong team and Board of Directors to assist and execute on these plans. Our Board includes some of the most respected names in their respective industries, with Peter McDonough, the former President of Diageo North America; Lorne Gertner, founder of Tokyo Smoke and the Cronos Group; Dan Ballister of Smoke Hall Foods; and Paul Uhlir. CEO of one of the largest digital marketing agencies in the Pacific Northwest.”
According to Snyder, the company remains excited about current market opportunities at-hand and intends to continue to update the market in due course as it executes upon its strategic initiatives.
Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking information contained in this news release includes, but is not limited to, the delisting of the Common Shares from the TSXV, the listing of the Common Shares on the CSE and the future growth plans of the Company. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events and are therefore based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Neither the TSXV, the CSE nor their Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information about Empower please see the Company’s website at www.empowerclinics.com or contact the following: